Cardiovascular safety assessment in early-phase clinical studies: A meta-analytical comparison of exposure-response models

CPT: Pharmacometrics and Systems Pharmacology

Volumn 5, Issue 6, 2016, Pages 324-335

  Conrado, D J ^a   Chen, D ^a   Denney, W S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CARDIOVASCULAR AGENT; ERTUGLIFLOZIN; NIROGACESTAT; PF 02341272; PF 03463275; PF 04064900; PF 04236921; PF 04287881; PF 04308515; PF 04831035; PF 04958242; PF 05161704; PF 05190457; PF 05200145; SULOPENEM ETZADROXIL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ARTICLE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ELECTROCARDIOGRAM; HUMAN; META ANALYSIS; PHARMACOKINETICS; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; RISK ASSESSMENT; RR INTERVAL; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; STATISTICAL MODEL; THEORETICAL MODEL;

BIOMARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROCARDIOGRAPHY; HUMANS; LINEAR MODELS; LONG QT SYNDROME; MODELS, THEORETICAL;

EID: 84976334288     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12086     Document Type: Article

References (45)

1. US Food and Drug Administration (FDA) Critical Path Initiative, the Cardiac Safety Research Consortium (CSRC). . https: //www.cardiac-safety.org/. Accessed 17 June 2013
2. Prospective Studies Collaboration, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet 370, 1829-1839 (2007
3. Sager, P. et al. Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am. Heart J.165 477-488 2013 165, 477-488 (2013
4. Bemelmans, R.H. et al. The risk of resting heart rate on vascular events and mortality in vascular patients. Int. J. Cardiol. 168, 1410-1415 (2013
5. Kannel, W.B., Kannel, C., Paffenbarger, R.S. Jr & Cupples, L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J. 113, 1489-1494 (1987
6. Okin, P.M. et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur. Heart J. 31, 2271-2279 (2010
7. Tverdal, A., Hjellvik, V., & Selmer, R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379, 843 men and women aged 40-45 years. Eur. Heart J. 29, 2772-2781 (2008
8. Roden, D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004
9. Yap, Y.G., & Camm, A.J. Drug induced QT prolongation and torsades de pointes. Heart 89, 1363-1372 (2003
10. International Conference on Harmonisation (ICH) E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions & answers (R2). Current version dated 21 March 2014. http: //www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-QAs-R2-Step4.pdf. Accessed 3 April, 2015
11. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for Industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005. http: //www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf Accessed 3 April, 2015
12. Darpo, B. et al. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin. Pharmacol. Ther. 97, 326-335 (2015
13. Piotrovsky, V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J. 7, E609-E624 (2005
14. Tornøe, C.W., Garnett, C.E., Wang, Y., Florian, J., Li, M., & Gobburu, J.V. Creation of a knowledge management system for QT analyses. J. Clin. Pharmacol. 51, 1035-1042 (2011
15. Standing, J.F., Hammer, G.B., Sam, W.J., & Drover, D.R. Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. Paediatr. Anaesth. 20, 7-18 (2010
16. Woo, S.K., Kang, W.K., & Kwon, K.I. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clin. Pharmacol. Ther. 71, 246-252 (2002
17. Friberg, L.E., Isbister, G.K., & Duffull, S.B. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br. J. Clin. Pharmacol. 61, 177-190 (2006
18. Grosjean, P., & Urien, S. Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval. J. Clin. Pharmacol. 52, 329-338 (2012
19. Parkinson, J. et al. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. J. Pharmacol. Toxicol. Methods 68, 357-366 (2013
20. Piotrovsky V, Van Peer A, eds. Cardiovascular safety data analysis via mixed-effects modelling [Abstract]. Population Approach Group in Europe (PAGE) 9th Meeting; 2000; Salamanca, Spain
21. Hempel, G., Karlsson, M.O., de Alwis, D.P., Toublanc, N., McNay, J., & Schaefer, H.G. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin. Pharmacol. Ther. 64, 622-635 (1998
22. Baek, I.H., Yun, M.H., Yun, H.Y., & Kwon, K.I. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Arch. Pharm. Res. 31, 814-821 (2008
23. Donnelly, R., Elliott, H.L., & Meredith, P.A. Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. Clin. Pharmacokinet. 26, 472-485 (1994
24. van Rijn-Bikker, P.C. et al. Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in black and white hypertensive patients. Clin. Pharmacokinet. 52, 793-803 (2013
25. Tanigawara, Y., Yoshihara, K., Kuramoto, K., & Arakawa, K. Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis. Drug Metab. Pharmacokinet. 24, 376-388 (2009
26. Troc-oniz, I.F., de Alwis, D.P., Tillmann, C., Callies, S., Mitchell, M., & Schaefer, H.G. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine. Clin. Pharmacol. Ther. 68, 18-27 (2000
27. Galeazzi, R.L., Benet, L.Z., & Sheiner, L.B. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin. Pharmacol. Ther. 20, 278-289 (1976
28. Whiting, B., Holford, N.H., & Sheiner, L.B. Quantitative analysis of the disopyramide concentration-effect relationship. Br. J. Clin. Pharmacol. 9, 67-75 (1980
29. Holford, N.H., Coates, P.E., Guentert, T.W., Riegelman, S., & Sheiner, L.B. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships. Br. J. Clin. Pharmacol. 11, 187-195 (1981
30. Uematsu, T., Kanamaru, M., & Nakashima, M. Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (1)-sotalol in healthy volunteers. J. Pharm. Pharmacol. 46, 600-605 (1994
31. Meuller, P., Cohen, T., de Gasparo, M., Sioufi, A., Racine-Poon, A., & Howald, H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur. J. Clin. Pharmacol. 47, 231-245 (1994
32. Porchet, H.C., Piletta, P., & Dayer, P. Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. Eur. J. Clin. Pharmacol. 42, 655-661 (1992
33. Ragueneau, I., Laveille, C., Jochemsen, R., Resplandy, G., Funck-Brentano, C., & Jaillon, P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin. Pharmacol. Ther. 64, 192-203 (1998).
34. Le Coz, F., Funck-Brentano, C., Morell, T., Ghadanfar, M.M., & Jaillon, P. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin. Pharmacol. Ther. 57, 533-542 (1995
35. Shi, J., Ludden, T.M., Melikian, A.P., Gastonguay, M.R., & Hinderling, P.H. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J. Pharmacokinet. Pharmacodyn. 28, 555-575 (2001
36. Leaer, S. et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J. Am. Coll. Cardiol. 46, 1322-1330 (2005
37. Phillips, L., Grasela, T.H., Agnew, J.R., Ludwig, E.A., & Thompson, G.A. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. Clin. Pharmacol. Ther. 70, 370-383 (2001
38. Conrado, D.J., Chen, D., & Denney, W.S. Cardiovascular safety prediction for early drug development: a meta-analytical comparison of modeling methods. American Society of Clinical Pharmacology and Therapeutics Annual Conference; 2014; Atlanta, GA
39. Salkind, N.J., & Rasmussen, K. Akaike Information Criterion. Encyclopedia of Measurement and Statistics (Thousand Oaks, CA: SAGE Publications, 2007
40. Akaike, H. A new look at the statistical model identification. IEEE Trans. Automat. Contr. 19, 716-723 (1974
41. Kelbaek, H., Munck, O., Christensen, N.J., & Godtfredsen, J. Central haemodynamic changes after a meal. Br. Heart J. 61, 506-509 (1989
42. Masuo, K., Mikami, H., Ogihara, T., & Tuck, M.L. Mechanisms mediating postprandial blood pressure reduction in young and elderly subjects. Am. J. Hypertens. 9, 536-544 (1996
43. Heseltine, D., Potter, J.F., Hartley, G., Macdonald, I.A., & James, O.F. Blood pressure, heart rate and neuroendocrine responses to a high carbohydrate and a high fat meal in healthy young subjects. Clin. Sci. (Lond). 79, 517-522 (1990
44. Lipsitz, L.A., Nyquist, R.P. Jr, Wei, J.Y., & Rowe, J.W. Postprandial reduction in blood pressure in the elderly. N. Engl. J. Med. 309, 81-83 (1983
45. Bloomfield, D.M. Incorporating exposure-response modeling into the assessment of QTc interval: a potential alternative to the thorough QT study. Clin. Pharmacol. Ther. 97, 444-446 (2015